Clinical Trials /

A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck

NCT02207439

Description:

This is a Phase II trial of definitive chemoradiotherapy (CTRT) given with the protease inhibitor,Nelfinavir (NFV), in patients with locally advanced head and neck. Eligible patients will receive a "lead-in" period of Nelfinavir (1250 mg po bid) for 7-14 days prior to initiation of CTRT. Nelfinavir will then be given concurrently with platinum-based chemotherapy and radiation therapy (planned total dose of 70 Gy over 7 weeks).

Related Conditions:
  • Head and Neck Squamous Cell Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck
  • Official Title: A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck

Clinical Trial IDs

  • ORG STUDY ID: UPCC 15313
  • NCT ID: NCT02207439

Conditions

  • Stage III, IVa, or IVb Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, or Hypopharynx

Interventions

DrugSynonymsArms
Nelfinavir (Viracept®) 1250 mgSingle Arm Phase 2
FMISOSingle Arm Phase 2

Purpose

This is a Phase II trial of definitive chemoradiotherapy (CTRT) given with the protease inhibitor,Nelfinavir (NFV), in patients with locally advanced head and neck. Eligible patients will receive a "lead-in" period of Nelfinavir (1250 mg po bid) for 7-14 days prior to initiation of CTRT. Nelfinavir will then be given concurrently with platinum-based chemotherapy and radiation therapy (planned total dose of 70 Gy over 7 weeks).

Trial Arms

NameTypeDescriptionInterventions
Single Arm Phase 2Experimental
  • Nelfinavir (Viracept®) 1250 mg
  • FMISO

Eligibility Criteria

        Inclusion Criteria:

          -  Patients ≥ 18 years old.

          -  Histologically confirmed diagnosis of squamous cell carcinoma of the oral cavity,
             oropharynx, larynx, or hypopharynx stages III, IVa, or IVb, p16-negative on
             immunohistochemistry

          -  Determined by the treating physician to be a candidate for organ preserving,
             concurrent standard chemotherapy and radiation therapy to the head and neck with
             definitive intent.

          -  ECOG Performance Status 0-2

          -  Patients must sign an informed consent document that indicates they are aware of the
             investigational nature of the treatment in this protocol as well as the potential
             risks and benefits.

          -  The effects of EF5 on the developing human fetus are unknown. For this reason, women
             of childbearing potential and men must agree to use adequate contraception (hormonal
             or barrier method of birth control) prior to study entry, during study, until 1 month
             after completion of the final FMISO PET/CT scan. Should a woman become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately. Serum pregnancy testing will be required for women of
             childbearing potential.

          -  Ability to understand and the willingness to sign a written informed consent.

        Exclusion Criteria

          -  Prior radiation therapy to the head and neck

          -  Prior chemotherapy within the past 5 years

          -  Previous therapy with a human immunodeficiency virus (HIV) protease inhibitor

          -  Pregnant or lactating patients.

          -  Patients with known HIV disease. These patients have a high probability of treatment
             with anti-retroviral therapy which may interact with the nelfinavir.

          -  Absolute Neutrophil Count ≤ 1500 per mm3

          -  Platelet count ≤ 100,000 per mm3

          -  Serum creatinine > 1.5 times the upper limit of normal

          -  Serum AST or ALT > 2 times the upper limit of normal

          -  Serum bilirubin > 1.2 mg/dl

          -  Weight loss of > 10% over the past 6 months which is due to tumor wasting syndrome

          -  Distant metastases

          -  Patients receiving the following drugs that are contraindicated with NFV will be
             excluded: Antiarrhythmics:amiodarone, quinidine, Antimycobacterial: rifampin, Ergot
             Derivatives:dihydroergotamine, ergonovine, ergotamine, methylergonovine, Herbal
             Products: St.John's wort (hypericum perforatum), HMG-CoA Reductase Inhibitors:
             lovastatin,simvastatin, Neuroleptic:pimozide, Proton Pump Inhibitors,
             Sedative/Hypnotics: midazolam, triazolam,

          -  Patients receiving the following drugs will be clinically evaluated as to whether
             dosage/medication can be changed to permit patient on study: Anti-Convulsants:
             carbamazepine, Phenobarbital, Anti-Convulsant:phenytoin, Anti-Mycobacterial:rifabutin,
             PDE5 Inhibitors: sildenafil, vardenafil, tadalafil, HMG-CoA: Reductase Inhibitors:
             atorvastatin, rosuvastatin, Immuno-suppressants: cyclosporine,tacrolimus, sirolimus,
             Narcotic Analgesic: methadone, Oral Contraceptive:ethinyl estradiol, Macrolide
             Antibiotic:azithromycin, Inhaled/nasal steroid fluticasone, Antidepressant: trazodone.

          -  Women of childbearing potential who have a positive result on screening urine
             pregnancy test.

          -  Subjects with moderate-severe renal disease.

          -  History of allergic reactionsattributed to Flagyl (metronidazole), which has a
             chemical structure similar to FMISO.

          -  Uncontrolled intercurrent illness including, but not limited to symptomatic congestive
             heart failure, unstable angina pectoris, or psychiatric illness/social situations that
             would limit compliance with study requirements.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Determine locoregional control
Time Frame:5 years
Safety Issue:
Description:To determine locoregional control for patients with locally advanced, HPV-negative head and neck cancer, treated with definitive NFV + CTRT and compare it to published historical results.

Secondary Outcome Measures

Measure:Assessment of Nelfinavir on hypoxia
Time Frame:5 years
Safety Issue:
Description:To determine the effect of NFV on hypoxia as assessed by F-MISO PET/CT scanning.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Abramson Cancer Center of the University of Pennsylvania

Last Updated